Connect with us

Business

Shortage of medicines likely to exacerbate from Paracetamol to life-saving drugs: SLCPI

Published

on

From left: Sri Lanka Chamber of the Pharmaceutical Industry Treasurer Dinesh Athapaththu, Vice President Azam Jaward, Senior Vice President M. Prathaban, President Sanjiva Wijesekera, Immediate Past President Kasturi Chellaraja Wilson, Council Members Adrian Basnayake and Jude Fernando

by Sanath Nanayakkare

The current shortage of Paracetamol and Panadol in the market could aggravate to a situation where life-saving drugs would not be available to patients in a few months, Sri Lanka Chamber of the Pharmaceutical Industry (SLCPI) warned yesterday.

“This could happen if the US dollar shortage is not properly addressed and a realistic pricing formula for imported medicines is not introduced forthwith by the authorities,” they said.

“At present, the shortage of medicines is about 5%. One might say it is small or unimportant as to be not worth considering. But in 4-6 weeks from now it could increase to about 25%,” they warned.

SLCPI made these comments at a press briefing held at Taj Samudra Colombo.

“We have a fear. We want to update the general public of Sri Lanka on the current situation with regard to medicine imports because what is on the horizons is not good. Delays at the National Medicines Regulatory Authority (NMRA), the unrealistic price mechanism and the dollar crisis are biting our industry. The dollar crisis is common to every industry, but we also have a serious problem as medicine importers. Until last month, we didn’t have a major crisis. But this month and in the last two weeks, the banks have been advised to prioritise allocation of dollars for fuel purchases and it appears that medicine imports have received de-prioritisation on the list of essential imports. If this trend continues, we will have a serious problem in even importing life-saving drugs. At the moment, it is under control. We have to inform the general public of the evolving situation,” Azam Jaward, Vice President, SLCPI said.

“The last price increase on drugs was allowed in August 2021 when the USD was trading at Rs. 194. Now the dollar has incresed to Rs. 203 which is the ‘published rate’ by the Central Bank of Sri Lanka, but unfortunately there is no mechanism to address the current disparity in the exchange rate. We need asustainable pricing mechanism which addresses the exchange rate, freight rate, current global prices, inflation, cost of fuel etc,” they said.

“Our industry is quite energy-driven. Some drugs need to be stored in temperatures between 2- 8 Celsius. Some need -20 Celsius. If we don’t have electricity, we face big issues. We have to run generators and multiple storage facilities. At present, we are managing it. But all of this depends on the availability of fuel. To run a generator for 7-8 hours a day, we need 2,000 litres of diesel per day,” they said.

“The NMRA charges dollars from us to register a product. They adjust it monthly based on the change of the exchange rate. The government has a fee- charging mechanism based on the US dollar. Then why don’t they do the same for drugs that are imported for sale? These are two conflicting policies,” they argued.

“We don’t need a price increase. Just amend the prices relative to the value of the dollar. For this we need an intervention by the Central Bank. If we can obtain a monthly allocation of USD 25-30 million per month, we believe that we can supply essential drugs to the general public without any disruption,” they said.

“We have had discussions with the authorities on these matters and we have submitted these facts for them to consider, but we have not yet achieved any results other than discussions.There is undue delay at the NMRA in granting the re-registration of products which have been available in the market for a considerable period, and new product registrations. With regulatory fees increasing by an average of 11-fold, the service of the regulator is below expectation,” they said.

Some excerpts of the SLCPI press statement are reproduced below.

“Over 85% of pharmaceutical products are imported, and these imports are paid for by US dollars. The current US dollar shortage in the country has increased the difficulty of importing essential medicines. In addition to this, companies have been unable to pay their dues. As a result, suppliers are no longer interested in supplying to Sri Lanka.”

“The situation is further worsened as banks find it difficult to honour the Letters of Credit (LCs) that are opened to import drugs. Banks delay opening the LCs until there are sufficient dollars. This has resulted in shipments being scheduled according to the availability of dollars and not according to the needs of the patients.”

acceptable pricing mechanism as well as immediately ironing out NMRA red tape for registrations are prerequisites for resolving this crisis.”

SLCPI serves as the representative of over 60 members who account for more than 80% of the private pharmaceutical industry, spanning manufacturers, importers, distributors and retailers. These stakeholders supply Sri Lankan patients with 1,200 molecules from 435 manufacturers from across the world.

SLCPI told The Island that banks ask them to purchase dollars from exporters to finance their medicine imports, but when they reach exporters to buy their dollars, they ask Rs. 245 per US dollar which is the price in the gray market. “So, how can we buy dollars from them and import and sell at controlled prices?” they said.



Business

Blue economy must move from ambition to investable projects – UNDP Country Economist

Published

on

Dr. Vagisha Gunasekera: ‘Four pathways’

By Ifham Nizam

The next wave of blue growth will depend not merely on recognising the value of the ocean, but on turning conservation, business and finance into a pipeline of credible, investable projects, UNDP Country Economist Dr. Vagisha Gunasekara said.

Addressing the 11th Annual Technical Sessions of the Biodiversity Action Forum 2026 at Shangri-La Colombo yesterday, Dr. Gunasekara challenged the private sector to move beyond broad commitments to ocean conservation and ask a more practical question: how can businesses, banks, investors and conservation organisations work together to create projects that are commercially viable while delivering measurable environmental and social benefits?

Delivering the keynote address on “The Next Wave of Blue Growth: Private Sector Entry Points for Productive Investment, Conservation, CSR and Blue Finance,” she said the discussion should move from why the ocean matters to how the private sector could participate in the blue economy.

‘The private sector is already in the blue economy, whether it recognises that exposure or not, she said.

The challenge, she added, was whether businesses would engage deliberately with the opportunities and risks associated with marine and coastal ecosystems or wait until environmental degradation translated into higher costs.

Dr. Gunasekara said healthy reefs, mangroves, seagrass beds, clean beaches and productive fishing grounds should no longer be viewed merely as environmental assets.

‘They are productive economic infrastructure, she said.

Such ecosystems underpin tourism, fisheries, food security, coastal protection, livelihoods, shipping and logistics, while supporting biodiversity and a range of economic sectors.

‘When a road is not maintained, there is an economic cost and we know it. But when a reef, a lagoon, a mangrove system or a fishing ground is not maintained, we often fail to see the cost until it is already showing up in lower productivity, weaker tourism value, higher risk and lost livelihoods, she said.

For Sri Lanka, this has particular significance given the country’s extensive maritime space.

‘We are more ocean than island, Gunasekara said, pointing out that the country’s economic imagination had not yet fully caught up with its geographical reality.

‘When we talk about the economy, we talk about agriculture, industry, tourism, trade, investment and infrastructure. But how often do we treat the ocean as infrastructure? Too often, we just treat it as scenery, she said.

Gunasekera stressed that marine degradation was not simply an environmental problem but increasingly a business risk.

Tourism and hospitality depend on beaches, reefs, marine life and clean coastal environments, while seafood and aquaculture depend on healthy ecosystems and responsible production.

Coastal logistics and infrastructure require climate-resilient shorelines and predictable planning, while coastal real estate faces exposure to erosion, flooding and climate-related risks.

For finance and insurance, the challenge is increasingly about understanding, pricing and managing these risks.

‘These risks show up on hotels’ occupancy rates, they show up in fisher catch volumes, they show up in export access, they show up in insurance exposure, they show up in infrastructure damage, in the cost of capital as well, she said.

Gunasekara outlined four major pathways through which the private sector could engage with the blue economy.

The first is productive activity, including sustainable tourism, aquaculture, fisheries, value addition, cold chains, maritime logistics, vessel and marina services, blue technology, renewable energy and other marine services.

The second is CSR and ESG, where companies could move away from one-off initiatives, such as beach clean-ups, towards structured, long-term and measurable corporate engagement.

This could include supporting coastal community livelihoods, monitoring and citizen science, ocean literacy, supplier traceability and measurable nature-positive outcomes.

The third is conservation partnerships, involving private-sector engagement with marine protected areas, restoration sites and conservation landscapes.

Such partnerships, she stressed, should not be confused with privatising nature or weakening public oversight.

Instead, the question should be how business could support effective management, visitor services, restoration and community-based conservation within clear regulatory frameworks.

The fourth pathway is finance, covering blended finance, blue bonds, guarantees, reef insurance, blue carbon, payments for ecosystem services, conservation loans and bankable project pipelines.

Continue Reading

Business

Union Bank recognised among Sri Lanka’s Top 20 Women-Friendly Workplaces

Published

on

(L to R) Nilusha Wanasinghe, Senior Manager – Marketing Union Bank, Nayomini Weerasooriya Founder/Editor of Satyn Magazine, Dr Samantha Rathnayake Head of the Panel of Judges, Devani Konara Chief Manager Human Resources and Thishani Dissanayake, Vice President – Marketing, of Union Bank.

Union Bank has been recognised at the Satyn Women-Friendly Workplace Awards 2026 for the second consecutive time, reaffirming the Bank’s commitment to building a diverse, inclusive workplace where women are empowered to lead, grow and thrive. Thishani Dissanayake, Vice President Marketing said “Union Bank continues to support and empower women at every level providing diverse opportunities for growth and this award is a proud reflection of the dedication, efforts and strength of all women at Union Bank”.

Continue Reading

Business

Seylan Bank appoints Krishan Thilakaratne Deputy Chairman

Published

on

Krishan Thilakaratne

Seylan Bank PLC has announced the appointment of Krishan Thilakaratne, Non‑Executive Director, as the Deputy Chairman of the Board with effect from 17th August 2026.

Thilakaratne was appointed as a Non-Executive Director to the Board in 2018, and the progression to Deputy Chairman, reaffirms his long‑standing governance role and leadership capacity.

He currently serves as Director/CEO of LOLC Finance PLC and is a member of the Senior Management Team of LOLC Holdings PLC.

Thilakaratne carries over three decades of experience in banking and finance. He began his career at Seylan Bank in September 1990, at the age of 19, as a Banking Assistant, before joining LOLC Group in 1995. Today, he counts more than 31 years of expertise in management, credit, channel management, marketing, factoring, portfolio management, and Islamic finance.

He holds extensive international exposure, serving on boards in Southeast Asia and Central Asia, including the Philippines, Indonesia, Pakistan, Kyrgyzstan, Kazakhstan, Tajikistan, Uzbekistan, and Egypt. His leadership roles extend to LOLC Moliya, Tajikistan, OJSC Micro Finance Company ‘ABN’, Kyrgyzstan, Finance, Kazakhstan, Prasac Microfinance Institution Ltd, Cambodia, LOLC Egypt, and additionally advising Lombard Micro Finance Company in Tajikistan.

In Sri Lanka, Thilakaratne has contributed significantly to the financial services sector, serving as a Board Member of the Credit Information Bureau of Sri Lanka (CRIB), Commercial Insurance Brokers (Pvt) Ltd. He has also held the position of Chairman of the Finance Houses Association of Sri Lanka (FHASL), the apex body for Non‑Bank Financial Institutions.

A Passed Finalist of the Chartered Institute of Management Accountants (CIMA) UK and Associate Member of the Institute of Bankers of Sri Lanka (AIB), Thilakaratne has completed the Strategic Leadership Training Programme in Microfinance at Harvard Business School, USA.

Continue Reading

Trending